1 Min Read
Jan 10 (Reuters) - Avadel Pharmaceuticals Plc:
* AVADEL PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR FT 218 FOR THE TREATMENT OF NARCOLEPSY Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.